Guide to PSA, Free

WRITTEN BY
Updated: 05/22/2025|12 min read

Summary

Prostate-specific antigen (PSA) is a protein produced by the prostate gland in men. Free PSA is the portion of PSA in the blood that isn't bound to proteins. Testing free PSA alongside total PSA can help differentiate between benign conditions and prostate cancer, particularly when total PSA falls in the diagnostic gray zone.

Why It Matters

PSA is produced in the prostate gland. Its primary function is to liquefy seminal fluid after ejaculation, helping sperm move more freely. In healthy men, very little PSA escapes into the bloodstream.

When prostate cells are damaged or when prostate disease is present, more PSA leaks into the bloodstream, raising blood PSA levels.

When in the bloodstream, PSA exists in two main forms: complexed (bound to proteins like alpha-1-antichymotrypsin) and free (unbound).

Cancerous and non-cancerous conditions affect these two forms differently. Prostate cancer tends to release more complexed PSA into circulation, while benign conditions like benign prostatic hyperplasia (BPH) and prostatitis (inflammation of the prostate) tend to release relatively more free PSA. 

The free PSA test can be helpful when total PSA falls within the diagnostic gray zone (typically 4-10 ng/mL). 

PSA testing allows physicians to identify potential cancers before symptoms appear. This early detection has significantly improved prostate cancer treatment outcomes. However, context and a healthcare professional are essential when interpreting free PSA results, as numerous factors beyond cancer can influence levels, and false positives can occur, leading to unnecessary biopsies.

Associated Symptoms 

Free PSA is a laboratory finding rather than a medical condition itself. However, conditions associated with abnormal free PSA levels may present with the following symptoms:

  • Difficulty starting or stopping urination (may indicate enlarged prostate or cancer)
  • Weak or interrupted urine stream 
  • Frequent urination, especially at night 
  • Pain or burning during urination 
  • Blood in urine or semen (could suggest various conditions, including cancer)
  • Pain in the lower back, hips, or upper thighs (possible with advanced prostate cancer)
  • Painful ejaculation (can occur with prostatitis or other conditions)
  • Pelvic discomfort or pressure (may be associated with an enlarged prostate)

It's important to note that many men with abnormal PSA results, including free PSA, may experience no symptoms at all, particularly in early-stage prostate cancer. This is why screening through PSA testing can be valuable for early detection.

Lifestyle Factors That Can Impact It

Activities that can positively impact free PSA levels include:

  • Regular exercise: Moderate to vigorous physical activity may help maintain healthy PSA levels.
  • Healthy diet: Diets high in fruits, vegetables, and plant-based proteins have been associated with lower PSA levels and better prostate health.
  • Maintaining weight: Obesity can lower circulating PSA levels due to hemodilution from higher blood volume, but it's linked to a higher risk of aggressive prostate cancer and worse outcomes, not necessarily cancer incidence overall.

Activities that can negatively impact free PSA levels include:

  • Smoking: Tobacco use can increase inflammation throughout the body, potentially affecting prostate health and PSA levels.
  • Excessive alcohol: Heavy drinking may influence hormone levels and increase inflammation, potentially affecting PSA.

Other Factors That Can Impact It

Genetic Conditions

  • Family history of prostate cancer: Men with first-degree relatives (father, brother) who have had prostate cancer have a higher risk of developing it.

Medical Conditions

  • Benign prostatic hyperplasia (BPH): This is a non-cancerous enlargement of the prostate, and can raise PSA levels.
  • Prostatitis: Inflammation of the prostate can damage the prostate's cells, allowing more PSA to leak into the bloodstream.
  • Prostate cancer: Cancerous cells disrupt the normal prostate tissue structure, increasing PSA leakage into the blood.
  • Urinary tract infection: Inflammation near the prostate can cause PSA elevation due to inflammation.
  • Recent prostate procedures: Any manipulation of the prostate (biopsy, surgery, etc.) can release additional PSA into the bloodstream.

Medications and Supplements

  • 5-alpha reductase inhibitors (finasteride, dutasteride): Decrease total PSA by about 50% by reducing prostate volume and inhibiting the conversion of testosterone to dihydrotestosterone, but may not significantly affect the free PSA percentage
  • Statins: May reduce PSA levels through anti-inflammatory effects and by lowering cholesterol, which is needed for testosterone production
  • Thiazide diuretics: Can potentially lower PSA levels through mechanisms related to fluid balance and hormonal changes
  • Nonsteroidal anti-inflammatory drugs (NSAIDs): May decrease PSA levels by reducing inflammation in the prostate, as inflammation can cause PSA leakage into the bloodstream
  • Testosterone replacement therapy: Can increase PSA levels by stimulating prostate tissue growth and metabolism, requiring careful monitoring during treatment
  • Certain herbal supplements: Some herbal preparations like saw palmetto may affect PSA levels by altering prostate cell activity or through anti-inflammatory properties

Individual Factors

  • Age: PSA levels naturally increase with age as the prostate enlarges. This is why age-specific reference ranges are often used when interpreting results.
  • Race/ethnicity: African American men tend to have higher baseline PSA levels and higher rates of prostate cancer.
  • Prostate volume: Larger prostates naturally produce more PSA, even in the absence of disease.
  • Obesity: Fat tissue can influence hormone metabolism, potentially affecting PSA production and prostate health.

Testing Accuracy and Stability

Free PSA testing improves the specificity of prostate cancer detection when combined with total PSA, particularly in the 4-10 ng/mL range. However, several factors can affect its accuracy.

Factors That Can Affect the Accuracy of Your Test

  • Recent ejaculation (within 24 hours) might slightly raise total PSA in some men, but the effect is usually minimal and doesn't significantly impact free PSA or clinical decisions.
  • Vigorous exercise, especially cycling, in the 48 hours before testing
  • Digital rectal examination within the previous three days
  • Recent urinary tract infection or prostatitis
  • Prostate procedures (biopsy, surgery) within the previous 1-2 months 

How It Relates to Other Markers

Other markers can provide insights about health status when viewed alongside free PSA results. These tests may include:

  • Total PSA: Measures all forms of PSA in the bloodstream. Free PSA is interpreted in the context of total PSA.
  • % Free PSA: Measures the proportion of PSA not bound to proteins. Lower percentages of free PSA are associated with a higher likelihood of cancer.
  • PSA density: This is measured using an ultrasound exam and compares the PSA level to prostate size. Higher density may indicate cancer, as cancerous tissue produces more PSA per volume than benign tissue.
  • Prostate Health Index (PHI): Combines total PSA, free PSA, and a precursor form called [-2]proPSA. PHI offers improved cancer detection specificity.
  • 4Kscore Test: Incorporates four kallikrein markers (including total and free PSA) with clinical information to predict the risk of aggressive prostate cancer.
  • Digital rectal examination (DRE): Physical examination to assess prostate size, consistency, and presence of nodules.
  • Prostate MRI: Provides detailed images of the prostate, helping identify suspicious areas for targeted biopsy.

What Results May Mean in the Context of Other Markers

  • High PSA + Low Free PSA: When total PSA is moderately elevated (4-10 ng/mL), lower free PSA levels can suggest a higher likelihood of cancer.
  • Normal PSA + Low Free PSA: Unclear result; may warrant follow-up testing.
  • Low Free PSA + High PSA Density: May suggest a higher likelihood of cancer.
  • High Free PSA + Low PSA Density: Can suggest benign conditions like BPH.
  • Low Free PSA + Abnormal DRE: May suggest a higher risk of cancer requiring further investigation.

Follow-up Considerations

If free PSA is abnormal, your provider may make some of the following recommendations. You should always speak to your doctor if you have medical questions or before making medical decisions.

When Re-Testing May be Appropriate

  • Will vary based on circumstances and your provider's guidance.

Additional Testing Your Doctor May Consider

  • % Free PSA
  • Prostate MRI to visualize prostate anatomy and identify suspicious areas
  • PCA3 urine test to measure prostate cancer antigen 3, a genetic marker specific to prostate cancer
  • 4Kscore or PHI (Prostate Health Index), an advanced blood test that combines multiple biomarkers
  • EXO-DX, a urine-based exosome test that analyzes RNA biomarkers to help distinguish between aggressive and non-aggressive prostate cancer
  • Genetic testing for men with family history of prostate cancer
  • Prostate biopsy is the gold standard for diagnosis when PSA and other indicators suggest cancer but is typically done after other tests suggest it is warranted given the risks associated with it

When Additional Care May be Warranted

  • High PSA
  • Rapid rise in PSA
  • Any PSA elevation with urinary symptoms
  • Abnormal DRE findings
  • Family history of prostate cancer with any PSA elevation
  • Blood in urine or semen

Bibliography

References

1. Carroll, Peter R., et al. "NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016." Journal of the National Comprehensive Cancer Network, vol. 14, no. 5, 2016, pp. 509--519.

2. Carter, H. Ballentine, et al. "Early Detection of Prostate Cancer: AUA Guideline." Journal of Urology, vol. 190, no. 2, 2013, pp. 419--426. https://doi.org/10.1016/j.juro.2013.04.119

3. Hayes, John H., and Michael J. Barry. "Screening for Prostate Cancer with the Prostate-Specific Antigen Test: A Review of Current Evidence." JAMA, vol. 311, no. 11, 2014, pp. 1143--1149. https://doi.org/10.1001/jama.2014.2085

4. Mottet, Nicolas, et al. "EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent." European Urology, vol. 71, no. 4, 2017, pp. 618--629. https://doi.org/10.1016/j.eururo.2016.08.003

5. Adhyam, M., and A. K. Gupta. "A Review on the Clinical Utility of PSA in Cancer Prostate." Indian Journal of Surgical Oncology, vol. 3, no. 2, 2012, pp. 120--129. https://doi.org/10.1007/s13193-012-0145-1

6. Catalona, William J., et al. "Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer from Benign Prostatic Disease: A Prospective Multicenter Clinical Trial." JAMA, vol. 279, no. 19, 1998, pp. 1542--1547. https://doi.org/10.1001/jama.279.19.1542

7. Loeb, Stacy, and William J. Catalona. "The Prostate Health Index: A New Test for the Detection of Prostate Cancer." Therapeutic Advances in Urology, vol. 6, no. 2, 2014, pp. 74--77. https://doi.org/10.1177/1756287213513486

8. Thompson, Ian M., et al. "Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter." New England Journal of Medicine, vol. 350, no. 22, 2004, pp. 2239--2246. https://doi.org/10.1056/NEJMoa031918

9. Bossens, M. M., et al. "Kinetics of Prostate-Specific Antigen After Manipulation of the Prostate." European Journal of Cancer, vol. 31A, no. 5, 1995, pp. 682--685. https://doi.org/10.1016/0959-8049(95)00016-c

10. Zhang, J et al. "Obesity inversely correlates with prostate-specific antigen levels in a population with normal screening results of prostate cancer in northwestern China." Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas vol. 49,8 (2016): e5272. doi:10.1590/1414-431X20165272

11. National Cancer Institute. "Prostate-Specific Antigen (PSA) Test." National Cancer Institute, 2 Feb. 2025, https://www.cancer.gov/types/prostate/psa-fact-sheet. Accessed 2 Apr. 2025.​

Sign up for the Levels Newsletter